Medpace Holdings reported second-quarter 2026 earnings of $4.25 per share, up 37.1% year over year, beating the Zacks Consensus Estimate by 4.17%, and raised its full-year revenue guidance to $2.805-$2.885 billion. Net new business awards jumped 28.2% to $795.7 million, driving a net book-to-bill ratio of 1.13, while backlog rose 4.9% to $3.01 billion. The company repurchased approximately 706,000 shares for $294.7 million during the quarter, with $527 million remaining under its buyback authorization. Medpace now expects 2026 earnings between $17.25 and $17.95 per share, above the consensus estimate of $17.51, and management noted oncology accounted for more than half of second-quarter bookings.
Medpace Holdings IncRecord Q2 bookings and raised 2026 guidance beat estimates, with strong backlog growth.
Elevance Health Inc